leadf
logo-loader
RNS
viewAllergan

Citadel Group - Form 8.3 - Allergan plc

RNS Number : 5171M
Citadel Group
11 May 2020
 
























 

Ap 19

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.         KEY INFORMATION


























Name of person dealing (Note 1)

Citadel Group

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common Stock ISIN IE00BY9D5467

Date of dealing

08 May, 2020

























2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security

                    dealt in (Note 3)









Long

Short

Common Stock  ISIN  IE00BY9D5467

Number        (%)

Number      (%)

(1) Relevant securities

3,059,488 (0.93%)

3,224 (0.00%)

(2) Derivatives (other than options)

3,465,201 (1.05%)

0 (0.00%)

(3) Options and agreements to purchase/sell

0 (0.00%)

0 (0.00%)

Total

6,524,689(1.98%)

3,224 (0.00%)



























 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

























Long

Short


Number        (%)

Number      (%)

(1) Relevant securities



(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total































Ap 20






























1.         DEALINGS (Note 4)

 

(a)        Purchases and sales





























Purchase/sale

Common Stock ISIN IE00BY9D5467

Number of securities

Price per unit (Note 5)

65

192.15923077  USD

10

192.37  USD

10

192.38  USD

6

192.42  USD

126

192.51174603  USD

259

192.56942085  USD

10

192.61  USD

10

192.642  USD

50

192.73  USD

100

192.93  USD

-15

191.79  USD

-10

192.03  USD

-155

192.13658065  USD

-20

192.19  USD

-20

192.23  USD

-604

192.25013245  USD

-7

192.3  USD

-20

192.35  USD

-216

192.36657407  USD

-44

192.385  USD

-116

192.4  USD

-35

192.40142857  USD

-11

192.43181818  USD

-86

192.43459302  USD

-238

192.45163866  USD

-68

192.46382353  USD

-9

192.5  USD

-134

192.50365672  USD

-100

192.51  USD

-17

192.62470588  USD

-275

192.65872727  USD

-8

192.66875  USD

-37

192.71918919  USD

-337

192.77136499  USD

-67

192.80343284  USD

-100

192.83  USD

-15

192.83666667  USD

-20

192.84  USD

-22

192.97  USD

-5

193.01  USD

-50

193.0592  USD

-18

193.06277778  USD

-12

193.06833333  USD

-914

193.08  USD





















(b)        Derivatives transactions (other than options transactions)























Product name,

e.g. CFD

 ISIN

Nature of transaction

(Note 6)

 

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

























(c)        Options transactions in respect of existing relevant securities

 

(i)         Writing, selling, purchasing or varying























Product name, e.g. call option

Writing, selling, purchasing,

varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type,

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(Note 5)



























(ii)        Exercising
























Product name,

e.g. call option

Number of securities

Exercise price per unit

(Note 5)






























(d)        Other dealings (including transactions in respect of new securities) (Note 4)




























Nature of transaction

(Note 8)

      Details

      Price per unit

      (if applicable) (Note 5)







 



















Ap 21

















2.         OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 
















Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated

None














Is a Supplemental Form 8 attached? (Note 9)


NO

















 Date of disclosure:

11 May, 2020

 Contact name:

Katie Bonds

 Telephone number:

020 7645 9700

If a connected EFM, name of offeree/offeror with which connected

n/a

If a connected EFM, state nature of connection (Note 10)

n/a





 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEBDGDUDGBDGGB

Quick facts: Allergan

Follow
NYSE:AGN

Price: -

Market Cap: -

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

16 min read